ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO988

Clinicopathologic Features of CKD Kidney Precision Medicine Project (KPMP) Participants

Session Information

Category: Pathology and Lab Medicine

  • 1800 Pathology and Lab Medicine

Authors

  • Narasimhan, Ramya, Boston Medical Center, Boston, Massachusetts, United States
  • Caramori, M. Luiza A., Cleveland Clinic, Cleveland, Ohio, United States
  • Waikar, Sushrut S., Boston Medical Center, Boston, Massachusetts, United States
  • Mariani, Laura H., University of Michigan, Ann Arbor, Michigan, United States
  • Roberts, Glenda V., Kidney Research Institute, University of Washington, Seattle, Washington, United States
  • Henderson, Joel M., Boston Medical Center, Boston, Massachusetts, United States
  • Rosas, Sylvia E., Joslin Diabetes Center, Boston, Massachusetts, United States

Group or Team Name

  • Kidney Precision Medicine Project (KPMP).
Background

Patients with CKD have significant heterogeneity in the patterns of kidney (Kd) lesions. Herein, we analyzed research KPMP Kd biopsies (Bx) to determine if clinical features were associated with histopathologic patterns in CKD ppts with diabetic (DN) or vascular (VN) nephropathy.

Methods

Ppts recruited from 15 US centers underwent comprehensive clinical evaluation and research KdBx. Histopathology was assessed by two renal pathologists on whole slide images and consensus score assigned for morphologic features. Clinicopathologic diagnoses (Dx) were adjudicated by a committee of consortium members in 154 CKD Bx, and ppts assigned a primary Dx of DN, VN, “other”, or “could not determine."

Results

42% of Bx had DN and 32% had VN as primary Dx. Age was 58±12 vs. 63±11 yrs (p=0.02), and 32% vs. 10% were of Hispanic ethnicity (p=0.01) in the DN and VN cohort, respectively. UACR (median; 95%CI) was higher (p<0.005) in DN [1176 (833-2393)] vs. VN [191 (39-579) mg/g] ppts. There were no differences between DN and VN ppts in the proportion of females (45 vs.40%) and African Americans (32 vs.35%), or in BMI (32±7 vs. 30±6 Kg/m2 ) and eGFR (55±22 vs. 47±18 mL/min/1.73 m2). The presence and/or severity of global and segmental glomerulosclerosis, podocytopathy, interstitial fibrosis/tubular atrophy, and interstitial eosinophils were not different between groups, while arteriolar hyalinosis was more frequent in DN ppts (Table). Acute tubular injury was seen in the majority of DN and VN Bxs.

Conclusion

Protocol research KdBx are feasible and safe in CKD. Relative to KPMP CKD entry criteria, most ppts exhibited features of DN or VN and varying extent of chronic histopathologic changes. Unanticipated acute histopathologic changes including acute tubular injury were also commonly observed. Work is underway to further examine relationships between clinical features, histopathologic and -omics findings in KPMP ppts.

Histopathologic FeaturesDN (n=65)
%
VN (n=48)
%
p-value
Interstitial fibrosis, moderate to severe53.939.60.18
Tubular atrophy, moderate to severe56.941.70.12
Tubular casts36.952.10.12
Interstitial eosinophils18.56.30.09
Arteriolar hyalinosis95.479.20.01
Arteriosclerosis, severe32.345.90.21

DN=diabetic nephropathy; VN=vascular nephropathy

Funding

  • NIDDK Support